Your GLP-1 Questions, Answered: Side Effects, Pipeline & Price
Second EBN-hosted webinar addressing employers' most pressing questions around the risks and side effects of GLP-1s.
Read Article
Second EBN-hosted webinar addressing employers' most pressing questions around the risks and side effects of GLP-1s.
Read Article
What does the evidence say about GLP-1 efficacy for weight loss? Omada answers frequently asked questions from benefit plan managers and payers as they navigate the use of GLP-1s for weight loss.
Read Resource
The price of GLP-1 medication is a concern for stakeholders throughout the healthcare industry. Omada breaks down the list of GLP-1s by FDA approval stage, & what more GLP-1s could mean for costs.
Read Article
What you need to know about GLP-1s, and how Omada can help
Learn MoreSee why Omada is a trusted virtual health partner of manufacturing companies across the US for diabetes prevention and management. Omada's programs deliver real outcomes for weight loss and engagement
Read Resource
GLP-1s are effective options for weight management, but costs and side effects matter. Dive into the history and overview of GLP-1s in our 2-minute video.
Watch Video
GLP-1s like Ozempic and Wegovy can be costly. Learn how high prices of GLP-1s can potentially impact the healthcare ecosystem in our 2-minute video.
Watch Video
GLP-1s like Ozempic are prescribed alongside lifestyle changes like diet and exercise. Watch this video to learn about their effectiveness and side effects.
Watch Video
Should patients be on GLP-1 medications long term? Watch this 2-minute video to learn what type of patients should be taking GLP-1s for weight loss.
Watch Video
In the fifth installment of Omada’s video blog series, we cover how we approach access to GLP-1 medications.
Watch Video
In the sixth installment of Omada’s video blog series, we cover why we are not prescribing GLP-1s to members.
Watch Video
In the last installment of our video series, we overview how support members with a unique layer of support for those who have chosen any “next level” obesity care.
Watch Video
The Stanford researcher and author says health behavior programs should be a key component of employee benefits packages. But CEOs and benefits leaders need to do more to make it happen
Read Resource
Behavior scientist Jennifer La Guardia on why “nudges” fall short and why effective care for members needs to be about more than outcomes
Read Resource
Health program designers have an array of tools to “nudge” people toward the correct behaviors. Science tells us which ones work, which don’t and why.
Read Resource
An array of mistaken assumptions has slowed adoption of science based approaches to improving health behavior.
Read Resource
In Conversation: How a Benefits Leader Sorted Through the Crowded Field of Virtual Care September 11-13, 2023 Health benefit leaders today have to balance many competing priorities,...
Read Article
GLP-1s have taken the healthcare industry – and pop culture – by storm as an effective class of medication to help treat chronic obesity. The exploding popularity of GLP-1s for weight loss has created
Watch Video
The first fully-virtual healthcare provider to earn this distinction, Omada continues to meet the industry’s best clinical standards with its renewed NCQA accreditation
Read Article
Explore examples of behavior change nudges, myths about health behavior, and why health behavior needs to be a higher priority in employee health plans.
Read Resource
Read Article
Loading More...